-
Mashup Score: 1“What’s That?” Two Simple Words That Saved a Life - 12 month(s) ago
“What’s that?” These two simple words led to Sue Manber’s early diagnosis of Merkel cell carcinoma, a rare, aggressive and deadly form of skin cancer.
Source: The Skin Cancer FoundationCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Mohs surgery improves survival in early-stage Merkel cell carcinoma - 12 month(s) ago
The findings were from a retrospective cohort study of 2,313 patients diagnosed from 2004 to 2018 with pathologically confirmed negative lymph node involvement treated with Mohs surgery or wide lesion excision.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#MohsSurgery improves survival in early-stage #MerkelCellCarcinoma 👉https://t.co/FSug0UV7d8 @MDedgeHemOnc https://t.co/nnGU1HQNrO
-
-
Mashup Score: 0Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
PUBLISHED: Radiation, Lymph Node Dissection, or Both: Management of #LymphNodeMicrometastases from #MerkelCellCarcinoma.https://t.co/GvyBE9Z9dW @McMastersKelly @SocSurgOnc https://t.co/EkYg6xovEc
-
-
Mashup Score: 0FDA Grants Accelerated Approval to Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma - The ASCO Post - 1 year(s) ago
By The ASCO Post Staff Posted: 3/23/2023 9:58:00 AM Last Updated: 3/23/2023 10:37:20 AM On March 22, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the PD-1 inhibitor retifanlimab-dlwr (Zynyz) for adult patients with metastatic or recurrent locally advanced Merkel cell…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA Grants Accelerated Approval to Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma https://t.co/GbdfG4olV6 @FDAOncology #skcsm #skincancer #MerkelCellCarcinoma #immunotherapy
-
-
Mashup Score: 0FDA approves new Merkel cell carcinoma treatment - 1 year(s) ago
This marks the first regulatory approval for retifanlimab-dlwr, a PD-1 inhibitor.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
FDA approves new #MerkelCellCarcinoma treatment 👉https://t.co/pZhDfHZLW6 @MDedgeHemOnc #Retifanlimab https://t.co/a8mnnN3FbL
-
-
Mashup Score: 0Merkel Cell Carcinoma - 1 year(s) ago
Get an overview about Merkel cell carcinoma, a rare, aggressive skin cancer, along with answers to your questions about diagnosis, treatment and risks.
Source: The Skin Cancer FoundationCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Approximately 3,000 new cases of #MerkelCellCarcinoma, a rare #skincancer, are diagnosed annually in the U.S. Experts expect this will increase to 3,250 cases diagnosed annually by 2025. Learn more: https://t.co/5IRxACVsI3 #RareDiseaseDay https://t.co/ZMWunct6Rq
-
-
Mashup Score: 1Adjuvant Treatment for Merkel Cell Carcinoma - 1 year(s) ago
Merkel cell carcinoma is a rare, aggressive cutaneous malignancy that originates due to the uncontrollable proliferation of Merkel cells.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
#Merkelcellcarcinoma (#MCC) is a rare, aggressive #cutaneous #malignancy that originates due to the uncontrollable proliferation of #Merkel cells. https://t.co/PMkh5bCZCD https://t.co/ob1KxvPnkS
-
-
Mashup Score: 0Nivolumab/Ipilimumab Induces Stark Overall Response Rate in Checkpoint Inhibitor–Naïve Merkel Cell Carcinoma - 1 year(s) ago
All 24 patients with Merkel cell carcinoma who received nivolumab plus ipilimumab responded to treatment, and 41% achieved complete responses.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nivolumab/Ipilimumab Induces Stark Overall Response Rate in Checkpoint Inhibitor–Naïve Merkel Cell Carcinoma #oncology #nursing #news #merkelcellcarcinoma #immunotherapy https://t.co/ArooD6o5EU
-
-
Mashup Score: 3Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II #MerkelCellCarcinoma @ABShannonMD @pennsurgery https://t.co/D8ed0fvWd0 #VisualAbstract @McMastersKelly https://t.co/OZShLbdzC3
-
-
Mashup Score: 0Preventing Misdiagnosis of Rare Skin Diseases - 2 year(s) ago
Thorough history taking is essential during the consultation and can help clinicians rule out other potential differential diagnoses.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
This article offers strategies to help prevent misdiagnosis of 2 #RareSkinDiseases: #MerkelCellCarcinoma and #ActinicPrurigo. https://t.co/6iPIIjvnoL
-
“What’s that?” These two simple words led to Sue Manber’s early diagnosis of #Merkelcellcarcinoma, a rare, aggressive type of skin cancer. Early detection is what saved her life. https://t.co/gjpZgPPo5c #ThisIsMCC #ThisIsSkinCancer #TheBigSee